 The FDA has granted Priority Review to Zogenix Incs NASDAQ: ZGNX supplemental marketing application seeking approval for Fintepla fenfluramine in Lennox-Gastaut syndrome LGS childhood-onset epilepsy. The agencys Prescription Drug User Fee Act PDUFA target action date is March 25, 2022. 